| Turkish Journal of Cancer |
| 2008, Volume 38, Number 1, Page(s) 005-011 |
|
[ Summary ]
[ Full Text ]
[ PDF ]
|
| The results of postoperative chemoradiotherapy in rectal cancer |
| MELEK GAMZE AKSU1, HAKAN BOZCUK2, AYLİN FİDAN KORCUM1, CENK AHMET ŞEN1, NİNA TUNÇEL1 |
1Akdeniz University Medical School, Departments of Radiation Oncology, Antalya-Turkey 2Akdeniz University Medical School, Departments of Medical Oncology Antalya-Turkey |
The aim of this study was to investigate the treatment results
of postoperative chemoradiotherapy (CRT) and the
prognostic factors of locally advanced rectal cancer. Sixty
nine patients with rectal cancer treated with postoperative
CRT were analyzed. Irradiation was given with a total
dose of 0.4 Gy in 28 fractions. They all received concurrent
- fluorouracil and leucovorin chemotherapy regimens
during radiotherapy. Clinical, pathologic and treatment
characteristics were analyzed using univariate and multivariate
Cox models. There were thirty-nine male and thirty
female patients; their median age was 8. Thirty patients
received 1 to 2 cycles of chemotherapy before concurrent
CRT, while 39 has started with CRT simultaneously. The
median follow-up was 2 months. Late intestinal toxicity
appeared in 7 patients and 5 of them had required intestinal
resections. Univariate analysis showed that number of
involved lymph nodes, AP-PA field technique and having
chemotherapy before CRT had significant impact on overall
survival (OAS). In multivariate analysis, high number of
involved nodes (p=0.004, HR: 1.09) and AP-PA technique
(p=0.017, HR: 4.48) were independent poor prognostic
factors for OAS. High number of involved nodes and APPA
technique were independent poor prognostic factors
for survival in patients with rectal carcinoma treated with
surgery and postoperative CRT. Our results show that
appropriate radiotherapy technique should be utilized for
rectal cancer patients in order to improve survival. [Turk J
Cancer 2008;38(1): -11]
|
|
[ Summary ]
[ Full Text ]
[ PDF ]
|
Turkish Journal of Cancer web sitesi Novartis Onkoloji'nin karşılıksız eğitim katkılarıyla hazırlanmıştır.
|